![]({"default":{"load":"default","w":"80","h":"53","src":"//img-s-msn-com.akamaized.net/tenant/amp/entityid/AAAlpSa.img?h=533&w=799&m=6&q=60&o=f&l=f&x=1991&y=1472"},"size3column":{"load":"default","w":"62","h":"42","src":"//img-s-msn-com.akamaized.net/tenant/amp/entityid/AAAlpSa.img?h=417&w=624&m=6&q=60&o=f&l=f&x=1991&y=1472"},"size2column":{"load":"default","w":"62","h":"42","src":"//img-s-msn-com.akamaized.net/tenant/amp/entityid/AAAlpSa.img?h=417&w=624&m=6&q=60&o=f&l=f&x=1991&y=1472"}})
The research, carried out at 10 hospitals across the Netherlands, involved women whose placentas had been underperforming taking sildenafil, a medication sold under the brand name Viagra.
Viagra, which dilates the blood vessels, is used for erectile dysfunction in men and is prescribed for people with high blood pressure. The hope, backed up by experimental research on rats, had been that the drug would encourage a better flow of blood through the placenta, promoting the growth of the child.
The trial was terminated last week when an independent committee overseeing the research discovered that more babies than expected were being born with lung problems
Of the 90 women in a control group, who took a placebo, three developed the same lung issues and no babies died.
Between 10 and 15 women are waiting to find out if their child has been affected.
It is feared the drug caused high blood pressure in the lungs, leading to the babies receiving too little oxygen. There is nothing to suggest the trial was mishandled.
“We have already notified Canadian researchers who are conducting a similar study. In any case, they have temporarily stopped their research.”
The research began in 2015 and was due to run until 2020, with the participation of 350 patients.
A spokesman for Amsterdam UMC said it believed the trial had been conducted properly, but would expect an external investigation to be launched.
The hospital said in a statement: “An interim analysis by Amsterdam UMC, location AMC, showed that sildenafil may be detrimental to the baby after birth. The chance of a disease of the blood vessels of the lungs appears to be greater and the chance of death after birth seems to have increased.
A trial in the UK, from which results were published last December, offered no convincing evidence either way to the drug’s efficacy, or suggested there was any risk to patients.
Ganzevoort told De Volkskrant: “It was buzzing at conferences. Foreign colleagues let slip that they sometimes prescribed it, with good results.
“I have experienced in my own consulting room that pregnant women asked for it. Whether they have ordered it via the internet? I do not know. Who can know.
“In the Netherlands, doctors are reasonably cautious. The effectiveness and safety of a drug must first be rigorously demonstrated through placebo-controlled studies before we prescribe it. Justly. That has only been demonstrated once again.”
